Technical Analysis for INCY - Incyte Corporation

Grade Last Price % Change Price Change
grade A 78.42 -0.32% -0.25
INCY closed down 0.32 percent on Friday, January 18, 2019, on 1.21 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical INCY trend table...

Date Alert Name Type % Chg
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Pocket Pivot Bullish Swing Setup -0.32%
Jan 17 Wide Bands Range Expansion -0.32%
Jan 17 Overbought Stochastic Strength -0.32%
Jan 16 New Uptrend Bullish 2.43%
Jan 16 Inside Day Range Contraction 2.43%
Jan 16 Wide Bands Range Expansion 2.43%
Jan 16 Overbought Stochastic Strength 2.43%
Jan 15 Pocket Pivot Bullish Swing Setup -0.43%

Older signals for INCY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary small molecule drugs for oncology and inflammation. The company markets JAKAFI, an oral janus associated kinase (JAK) inhibitor for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. Its product pipe line includes ruxolitinib, a JAK inhibitor, which is in Phase III clinical trial for polycythemia vera; Phase II trial for essential thrombocythemia; Phase II trial for pancreatic cancer; Phase I/II trial to treat solid tumors/other hematologic malignancies, as well as baricitinib, a JAK inhibitor, which is Phase III trial for rheumatoid srthritis, Phase IIb trial for psoriasis, and Phase II trial for diabetic nephropathy. The company's products in pipeline also comprise INCB28060 and INCB24360, which are Phase II clinical trial products for the treatment of solid tumors. It has a collaborative research and license agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; and Pfizer Inc. The company was founded in 1991 and is headquartered in Wilmington, Delaware.
Is INCY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 96.44
52 Week Low 57.0
Average Volume 1,685,449
200-Day Moving Average 67.5376
50-Day Moving Average 67.191
20-Day Moving Average 69.5775
10-Day Moving Average 75.853
Average True Range 3.0074
ADX 29.56
+DI 34.3788
-DI 10.881
Chandelier Exit (Long, 3 ATRs ) 70.5378
Chandelier Exit (Short, 3 ATRs ) 66.0222
Upper Bollinger Band 83.5811
Lower Bollinger Band 55.5739
Percent B (%b) 0.82
BandWidth 40.253243
MACD Line 3.5527
MACD Signal Line 2.5996
MACD Histogram 0.9531
Fundamentals Value
Market Cap 16.13 Billion
Num Shares 206 Million
EPS -0.79
Price-to-Earnings (P/E) Ratio -99.27
Price-to-Sales 18.19
Price-to-Book 23.14
PEG Ratio -1.27
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 80.78
Resistance 3 (R3) 80.87 80.19 80.38
Resistance 2 (R2) 80.19 79.59 80.14 80.25
Resistance 1 (R1) 79.30 79.22 78.96 79.21 80.12
Pivot Point 78.62 78.62 78.45 78.57 78.62
Support 1 (S1) 77.73 78.02 77.39 77.64 76.72
Support 2 (S2) 77.05 77.65 77.00 76.59
Support 3 (S3) 76.16 77.05 76.46
Support 4 (S4) 76.07